CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy and safety of Canagliflozin in subjects with type 2 diabetes mellitus on background metformin
DOI 10.1055/s-0033-1341910
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Januszewicz, F Lavalle González, J Davidson, R Qiu, C Tong, G Hamilton, G Meininger
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Question: Canagliflozin (CANA) is a sodium glucose co-transporter 2 inhibitor in development for the treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of CANA in subjects with T2DM inadequately controlled with metformin (MET). Methodology: In this randomised, double-blind, Phase 3 study, subjects with T2DM on stable MET (N = 1,284) received CANA 100 or 300 mg, sitagliptin (SI…
Zitieren
Zitierempfehlung
A Januszewicz, F Lavalle González, J Davidson, R Qiu, C Tong, G Hamilton, G Meininger (2013) Efficacy and safety of Canagliflozin in subjects with type 2 diabetes mellitus on background metformin. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0033-1341910
Mit CareLit weiterarbeiten